Comparing Kisqali vs Perjeta
| Kisqali (ribociclib) | Perjeta (pertuzumab) |
|
|---|
| Kisqali (ribociclib) | Perjeta (pertuzumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer, Breast Cancer - Metastatic. Perjeta may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
Popular comparisons
|
|||||||||||||||
| More about Kisqali (ribociclib) | More about Perjeta (pertuzumab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Kisqali has an average rating of 8.6 out of 10 from a total of 34 ratings on Drugs.com. 85% of reviewers reported a positive effect, while 3% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Kisqali side effects |
View all Perjeta side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Kisqali prices |
View all Perjeta prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
54.7 hours |
432 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 751 drugs are known to interact with Kisqali:
|
A total of 4 drugs are known to interact with Perjeta:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
March 13, 2017 |
June 08, 2012 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.